Supportive Management of Acute Vestibular Symptoms

The combination is relevant in clinical settings that involve acute or unstable symptom patterns, primarily addressing core issues stemming from disequilibrium and associated discomfort. It is commonly used across conditions presenting with acute episodes, helping to manage symptoms that interfere with daily functioning, such as those related to vestibular disorders.

The antivertigo component is commonly used to ease symptoms related to inner ear problems. The medication plays a role in managing symptoms that may become intense or disruptive, including severe vertigo, the associated nausea, and the reflex of vomiting. It is also applied in addressing the acute discomfort of motion sickness or travel sickness when supportive symptom management is appropriate.

“The primary goal is to provide supportive relief during difficult episodes by easing the overall symptom load.”

The dual components contribute to improved comfort during periods of heightened symptoms and assist with maintaining functional stability when symptoms are more noticeable.

---

Quick Fact: Support for Dizziness and Sickness The combination is designed to help patients cope more steadily with the concurrent presence of spinning sensations and sickness that often accompany inner ear disturbances.

Who can and cannot use Stugil?

Official regulatory documents define strict population eligibility for Stugil (Cinnarizine and Domperidone combination), primarily due to cardiac risks associated with the Domperidone component.

Eligibility Status	Excluded Population/Condition
Contraindicated	Patients with underlying cardiac diseases (e.g., congestive heart failure), QTc prolongation, or significant electrolyte disturbances.
Contraindicated	Patients with moderate or severe hepatic impairment or a Prolactin-releasing Pituitary Tumour.
Contraindicated	Individuals with gastrointestinal haemorrhage, mechanical obstruction, or perforation.
Not Recommended	Children younger than 12 years of age or those weighing less than 35 kg.

Use is restricted in several other groups. Caution is required for patients older than 60 years due to a documented increased risk of serious ventricular arrhythmias. For patients with severe renal impairment, official labeling mandates that the dosing frequency must be reduced. Use during pregnancy is not advisable, and use during lactation requires a decision to discontinue the drug or breastfeeding, as the Domperidone component is excreted in human milk.

Interactions with other medicines and products

Stugil, a combination of Cinnarizine and Domperidone, has officially documented interaction profiles primarily governed by the metabolic and pharmacodynamic properties of its two active ingredients.

Contraindicated Combinations

Co-administration is strictly restricted with two major classes of medicines due to serious risks:

• Potent CYP3A4 Inhibitors: Prohibited because they significantly increase the plasma concentration and exposure (AUC) of Domperidone, raising the risk of cardiac events. Examples include certain systemic azole antifungals and specific macrolide antibiotics.
• QTc-Prolonging Medicinal Products: Prohibited due to the additive risk of QTc prolongation and serious ventricular arrhythmia. This includes specific antiarrhythmics and certain antipsychotics.

Pharmacodynamic and Metabolic Interactions

Interaction Type	Interacting Substances/Conditions
Additive Sedative Effect	CNS depressants (including alcohol) and other central nervous system depressant agents due to the Cinnarizine component.
Absorption Alteration	Gastric Acidity Reducers (e.g., Cimetidine, PPIs) impair the oral bioavailability of Domperidone.
Population Restriction	Moderate or Severe Hepatic Impairment is a contraindication due to the risk of drug accumulation.

Co-administration with other anticholinergic drugs may result in an additive antimuscarinic action. Due to the absorption alteration, the product should preferably be taken after meals to diminish gastric irritation.

Modulating Vestibular & Central Balance Signals

This domain centers on the Cinnarizine component's action as a calcium channel blocker and H1 histamine receptor antagonist. By reducing calcium influx into inner ear sensory cells and influencing signals in the brain's vestibular nuclei, it modulates the transmission of neural signals related to motion and orientation, thereby reducing the magnitude of sensory input.

---

Influencing D2 Receptor Signaling in the Chemoreceptor Trigger Zone

This key action involves the Dopamine D2 receptor antagonism primarily provided by Domperidone, targeted at the Chemoreceptor Trigger Zone (CTZ) located outside the blood-brain barrier. This mechanism modulates the signal transmission within the central reflex arc that coordinates the physiological process of emesis upon detection of chemical or systemic triggers.

---

‍️ Modulation of Upper Gastrointestinal Motility

This peripheral mechanism is driven by Domperidone's antagonism of D2 receptors in the smooth muscle of the stomach and upper intestine. This action increases the local release of acetylcholine, which, in turn, enhances the force and coordination of peristalsis and influences the rate of transit of gastric contents.

How to Use Stugil

The general principles for using the Cinnarizine and Domperidone fixed-dose combination (FDC) outline how the medicine is taken, when it is taken, and for how long. The product is administered via the oral route only, as a fixed-dose tablet.

---

Dosing and Administration

The standard pattern for adults and adolescents (≥ 12 years and ≥ 35 kg) involves taking one tablet, typically with strengths of Cinnarizine 20 mg and Domperidone 15 mg, up to three times per day. To achieve optimal administration conditions, the tablet is generally taken 15 to 30 minutes before meals on an empty stomach, which facilitates the absorption of the Domperidone component. Doses are typically separated by an approximate 8-hour interval. The tablet is intended to be swallowed whole with water and must not be crushed or chewed.

---

Duration and Specific Constraints

The use of this combination is subject to a strict duration constraint: treatment should not usually exceed seven days (one week). This limited period defines the product as being for acute, short-term administration. If a dose is missed, the standard procedure is skipping the dose and resuming the regular schedule; a compensatory double dose must not be taken. Usage criteria also dictate that the medicine is not authorized for children under 12 years of age or those weighing less than 35 kg.

Research Evidence / Overview of Studies for Stugil

Evidence for use in Vertigo and Vestibular Disorders

This section will summarize the clinical trials and research studies evaluating patterns of symptom change associated with the study of Stugil in conditions characterized by the spinning sensation and balance issues associated with vertigo and inner ear (vestibular) disorders, including Ménière's disease.

Studies have been conducted to observe patterns of symptom change in patients experiencing various forms of vertigo. Research has explored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. Findings from controlled studies have described patterns observed in the studies related to the intensity and frequency of vertigo symptoms. Research has explored scenarios where the combination was studied alongside its individual components or other treatments. The evidence quality varies across studies, and research does not determine whether an individual will respond similarly.

---

Evidence for use in Motion Sickness and Associated Nausea/Vomiting

This section will outline research exploring the investigation of Stugil in subjects with motion sickness and associated nausea and vomiting. Stugil has been studied for its use in conditions associated with acute or disruptive episodes that can occur during travel. The research so far describes patterns related to outcomes reflecting daily functioning linked to motion sickness. What remains uncertain is the full extent of observed changes in a broad range of motion sickness severity, and how its observed patterns relate to those of other agents that have been studied for this indication.

---

Long-term Studies and Follow-up

Most of the clinical research on Stugil has focused on its effects over defined short-term time intervals. Long-term effects are not fully established, and there is limited information for outcomes beyond these initial periods.

---

Evidence in Special Populations

Studies in Older Adults and Children

In the case of older adults, research exploring the use of Stugil in this group is sometimes limited. Due to natural physiological changes with age, the way the body processes the compounds may be different, and this requires special attention in research. For the pediatric population, specific clinical trial data for children remain insufficient.

Studies in Patients with Coexisting Health Conditions

Individuals with other health issues can be excluded from initial trials or constitute small subgroups. Therefore, while Stugil was observed in patients with conditions marked by functional limitations, subgroup findings are uncertain.

---

What is Still Uncertain About Stugil

The factors that predict observed changes in symptoms for an individual patient are not yet clearly understood. The findings were mixed in some earlier studies before the fixed-dose combination was introduced, and data are still emerging which means that certainty remains low in some aspects of research. Long-term effects are not fully established, and research is ongoing.

Common questions about Stugil (FAQ)

Q: How is Stugil different from a common over-the-counter medicine used for similar symptoms?

Stugil is described in official documents as a Fixed-Dose Combination (FDC) drug with a unique dual mechanism. The combination is designed to stabilize the inner ear's balance signals (Cinnarizine) while also controlling the physical vomiting reflex (Domperidone). This combined approach is intended to provide comprehensive support that is distinct from medicines containing only a single agent.

Q: Does Stugil interact with hormonal birth control pills?

Official product information indicates that the Domperidone component can affect hormone levels by increasing prolactin. This hormonal change may lead to side effects such as menstrual cycle irregularities in women. Official guidance requires that all existing health conditions and concomitant medicines, including hormonal contraceptives, are discussed with a prescribing professional.

Q: Are there any specific foods or drinks, besides alcohol, that official documents advise avoiding with Stugil?

Official information addresses the impact of food and stomach acidity on absorption. Products that reduce gastric acidity can impair the absorption of the Domperidone component. Additionally, some pharmacokinetic studies suggest that consumption of high-fat meals can slow down the overall absorption and elimination of Domperidone.

Q: How quickly is Stugil typically expected to start having its intended effect?

The Domperidone component is typically absorbed relatively quickly after oral administration. Official pharmacokinetic data indicates that the highest concentration of Domperidone in the blood is often reached within 30 minutes to one hour. This timeframe is most consistent when the medicine is taken on an empty stomach.

Q: What are the official signs that Stugil is beginning to work as described?

The official therapeutic purpose of Stugil is the relief of severe symptoms associated with poor balance, including vertigo, dizziness, and compounded nausea. The main signs that the medicine is working as intended would be a reduction in the severity and frequency of these specific symptoms.

Q: Is Stugil classified as a controlled substance or a habit-forming medicine?

According to information from major regulatory regions, the active ingredients in Stugil, Cinnarizine and Domperidone, are not typically classified as controlled substances. This medicine is also generally not described in official labeling as a habit-forming or dependency-inducing drug.

Q: Does taking Stugil require routine blood tests or special monitoring?

Official product warnings describe that caution and medical oversight are required when prescribing to patients with specific health factors, such as underlying heart disease, existing cardiac rhythm abnormalities, or significant electrolyte disturbances. Regulatory information also indicates the medicine may affect the results of certain lab tests.

Q: If the benefits are not noticeable right away, does that indicate Stugil is not working for the user?

Official documents describe Stugil as a short-term treatment with a rapid absorption profile. Given the strict maximum treatment duration of seven days, official information suggests that patients communicate with their healthcare professional if therapeutic benefit is not observed within a reasonable timeframe.

Q: What is the average half-life of Stugil in the human body?

Official pharmacokinetic documents provide the plasma elimination half-life for the components of Stugil. The half-life for the Domperidone component is reported to be approximately 7-9 hours in healthy individuals. It is also noted that this half-life can be significantly extended in patients who have severe renal (kidney) impairment.

Q: Are there known differences in how Stugil affects men versus women?

Official warnings note that the risk of serious ventricular arrhythmias is described as potentially higher in female patients. Additionally, the drug's effect on prolactin hormone levels can cause hormone-related side effects, such as menstrual irregularities, primarily affecting women.

Q: Can Stugil affect the results of certain medical lab tests?

Official safety information indicates that this medication may affect the results of certain medical lab tests, such as liver function tests. Regulatory safety information indicates the importance of communicating with healthcare providers regarding all current medications before medical tests are performed.

Q: What is the general information about discontinuing Stugil treatment?

The official treatment duration for Stugil should not usually exceed seven days (one week), defining it as an acute, short-term course. Product information describes the risk that the original symptoms of vertigo and nausea may reappear if the medicine is discontinued.

How to Store and Dispose of Stugil?

Official labeling defines specific conditions to maintain the stability of Stugil (Cinnarizine/Domperidone) tablets. The medicine must be stored at a temperature below 30°C and should be kept in a cool and dry place. To prevent degradation, it must be protected from light and moisture. Stugil should be kept in its original container, tightly closed, and stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Requirements

Disposal of unused or expired tablets must adhere to local regulations. The preferred method is to use a community drug take-back program. If this is unavailable, the product should be mixed with an undesirable substance, such as coffee grounds, placed in a sealed container, and discarded in the household trash. Stugil must not be flushed down the toilet or poured into a drain.